Amanta Healthcare IPO GMP Today, Subscription Status, Allotment & Listing Updates

The Indian IPO market has been buzzing with activity in 2025, and one of the hottest issues that caught investor attention is the Amanta Healthcare IPO. With an overwhelming response from investors and an impressive oversubscription, this IPO is already the talk of the town. But what makes it even more interesting is the Grey Market Premium (GMP) trend, which often signals how the stock might perform on listing day.

In this detailed blog, we’ll cover everything investors need to know about Amanta Healthcare IPO GMP, subscription status, allotment date, financials, listing expectations, and expert analysis.

About Amanta Healthcare

Amanta Healthcare Ltd is a pharmaceutical company specializing in the production of sterile injectable formulations, IV fluids, and life-saving drugs. The company has carved a strong position in the healthcare sector by focusing on high-quality manufacturing, R&D-driven growth, and exports.

Key Business Segments:

• Intravenous (IV) Fluids – a critical product category in hospitals and emergency care.

• Sterile Injectables – used in critical care and specialty therapies.

• Exports – strong presence in both domestic and international markets.

The company operates modern manufacturing facilities, including the Hariyala plant in Gujarat, and adheres to strict global quality standards.

Over the last few years, Amanta Healthcare has shown consistent growth in both revenues and profits, which made its IPO highly attractive to retail and institutional investors alike.

Amanta Healthcare IPO Details

Here’s a snapshot of the IPO:

This was a fresh issue of shares, meaning all the funds raised will go directly to the company rather than existing shareholders. The proceeds are planned for expansion of manufacturing facilities and general corporate purposes.

Subscription Status: A Phenomenal Response

One of the biggest highlights of the Amanta Healthcare IPO was its massive oversubscription.

• Overall Subscription: ~82.6× (one of the highest in recent SME/mainboard issues).

• Retail Investors: ~55×

• Non-Institutional Investors (NIIs/HNIs): ~209×

• Qualified Institutional Buyers (QIBs): ~36×

Day-wise Subscription Trend

• Day 1 (1st Sept): IPO subscribed ~4.6×. Retail ~6.7×, NIIs ~5.8×, QIBs just ~0.04×.

• Day 2 (2nd Sept): Subscriptions jumped to ~19.6× overall. Retail ~23.3×, NIIs ~36.4×, QIBs ~0.53×.

• Day 3 (3rd Sept): Final tally ~82.6×, with NIIs leading the charge.

This strong demand shows high investor confidence in the company’s fundamentals and growth story.

Grey Market Premium (GMP) – The Sentiment Meter

The Grey Market Premium (GMP) is often seen as an indicator of how an IPO will perform on listing day. While it is unofficial and unregulated, many investors closely track GMP to estimate listing gains.

Amanta Healthcare IPO GMP Trend

• Day 1 (1st Sept): GMP stood around ₹25–29, signaling potential listing around ₹151 (23% gain).

• Day 2 (2nd Sept): GMP cooled to around ₹12, indicating ~9.5% premium (expected listing at ₹138).

• Day 3 (3rd Sept): GMP further softened to ₹8, pointing towards a listing price of ~₹134 (6% gain).

This shows that while the IPO attracted strong investor demand, the initial euphoria in the grey market settled down as subscription progressed.

Financial Performance of Amanta Healthcare

Investors always look beyond GMP and subscription to understand a company’s financial strength.

Key Financial Highlights (FY23–FY25):

• Revenue (FY25): ~₹276 crore

• Net Profit (FY25): ~₹10.5 crore (up ~190% compared to previous year)

• EBITDA Margin: Strong improvement due to efficient operations and higher exports.

• Debt Levels: Relatively stable, manageable compared to industry peers.

The strong profit growth in FY25, despite global pharma headwinds, is one of the key reasons why this IPO was seen as promising.

Strengths of Amanta Healthcare

1. Strong Market Demand for IV fluids and sterile injectables, both in India and abroad.

2. Robust Growth in Profits – nearly 190% YoY rise in FY25.

3. Experienced Management Team with pharma expertise.

4. Expansion Plans – IPO funds to be used for expanding Hariyala facility, adding capacity.

5. Growing Export Market – a key long-term growth driver.

Risks & Challenges

1. High Competition in pharma manufacturing from both Indian and global players.

2. Regulatory Risks – pharma industry faces strict compliance and frequent inspections.

3. GMP Volatility – as seen, GMP dropped sharply in 3 days, signaling cautious sentiment.

4. Dependency on Key Products – IV fluids form a major revenue chunk.

Peer Comparison

To understand valuation, it’s helpful to compare Amanta Healthcare with listed pharma peers such as:

• Kopran Ltd

• Aurobindo Pharma

• Gufic BioSciences

• Kabra Drugs Ltd

While Amanta is much smaller, it is operating in a niche sterile injectable segment where demand is structurally strong.

Expert Views on Amanta Healthcare IPO

• Market Analysts: Many brokerage houses indicated a “Subscribe” rating due to strong fundamentals and high oversubscription.

• Short-term Listing Gains: Analysts expect 6–10% premium on listing based on final GMP trends.

• Long-term Investors: Pharma sector outlook remains strong, and Amanta’s focus on expansion is positive for wealth creation over time.

Allotment & Listing Details

• Basis of Allotment: Finalized on 4 September 2025.

• Refunds/Share Credit: Processed on 5 September 2025.

• Listing Date: Expected on 8–9 September 2025 at NSE & BSE.

Investors can check their IPO allotment status through:

1. BSE/NSE IPO Status Checker

2. Registrar Website (Link Intime India)

3. Brokerage Platforms (Zerodha, Upstox, etc.)

What Should Investors Expect on Listing Day?

Based on subscription and GMP trends:

• Expected Listing Price: ₹134–138 (vs. issue price ₹126).

• Expected Gain: 6–10% premium.

• Risk Factor: GMP cooling suggests cautious sentiment; global market conditions on listing day could also influence outcome.

Final Verdict – Should You Invest in Amanta Healthcare IPO?

The Amanta Healthcare IPO generated massive interest, oversubscribed more than 82 times, and showed strong fundamentals. While the GMP started high and then cooled, it still points to a positive listing with modest gains.

Good for Short-Term Investors:

Chances of listing gains remain in the range of 6–10%, provided markets remain stable.

Attractive for Long-Term Investors:

Strong growth potential in sterile injectables, expanding capacity, and rising exports make Amanta Healthcare a promising pharma play.

Risks to Keep in Mind:

Volatile GMP, competitive industry, and regulatory challenges should be considered before long-term holding.

Conclusion

The Amanta Healthcare IPO reflects the strong appetite for quality pharma stocks in India’s booming IPO market. Oversubscription numbers were staggering, financials showed significant growth, and the GMP—though volatile—still signals healthy listing gains.

For retail investors, even small allotments in such an oversubscribed issue are valuable. For long-term investors, Amanta Healthcare’s growth strategy in critical-care pharma products makes it worth watching beyond the listing day excitement.